BUB1 Promotes Gemcitabine Resistance in Pancreatic Cancer Cells by Inhibiting Ferroptosis
Cancers · 18.04.2024 · 16 (8) · 1540
DOI: 10.3390/cancers16081540 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 18.04.2024. Verfasst von Weiming Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepato-Pancreatic Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325035, China. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Zhejiang Provincial Natural Science Foundation, Zhejiang Provincial Natural Science Foundation of China, Wenzhou Medical University.
Abstract (Originalsprache)
The development of chemotherapy resistance severely limits the therapeutic efficacy of gemcitabine (GEM) in pancreatic cancer (PC), and the dysregulation of ferroptosis is a crucial factor in the development of chemotherapy resistance. BUB1 Mitotic Checkpoint Serine/Threonine Kinase (BUB1) is highly overexpressed in PC patients and is closely associated with patient prognosis. However, none of the literature reports the connection between BUB1 and ferroptosis. The molecular mechanisms underlying GEM resistance are also not well understood. Therefore, this study first established the high expression levels of BUB1 in PC patients, then explored the role of BUB1 in the process of ferroptosis, and finally investigated the mechanisms by which BUB1 regulates ferroptosis and contributes to GEM resistance in PC cells. In this study, downregulation of BUB1 enhanced the sensitivity of PC cells to Erastin, and inhibited cell proliferation and migration. Mechanistically, BUB1 could inhibit the expression levels of Neurofibromin 2 (NF2) and MOB kinase activator 1 (MOB1), and promote Yes-associated protein (YAP) expression, thereby inhibiting ferroptosis and promoting GEM resistance in PC cells. Furthermore, the combination of BUB1 inhibition with GEM exhibited a synergistic therapeutic effect. These findings reveal the mechanisms underlying the development of GEM chemotherapy resistance based on ferroptosis and suggest that the combined use of BUB1 inhibitors may be an effective approach to enhance GEM efficacy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hepato-Pancreatic Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325035, China.
- Department of Breast Cancer, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou 325035, China.
ORCID-Profile: Xiang Zhou
Förderung
- Zhejiang Provincial Natural Science Foundation
- Zhejiang Provincial Natural Science Foundation of China
- Wenzhou Medical University
Zitieren
APA
Wang, W., Zhou, X., Kong, L., Pan, Z., & Chen, G. (2024). BUB1 Promotes Gemcitabine Resistance in Pancreatic Cancer Cells by Inhibiting Ferroptosis. Cancers, 16(8), 1540. https://doi.org/10.3390/cancers16081540
Vancouver
Wang W, Zhou X, Kong L, Pan Z, Chen G. BUB1 Promotes Gemcitabine Resistance in Pancreatic Cancer Cells by Inhibiting Ferroptosis. Cancers. 2024;16(8):1540. doi:10.3390/cancers16081540
BibTeX
@article{Wang2024,
author = {Wang, Weiming and Zhou, Xiang and Kong, Lingming and Pan, Zhenyan and Chen, Gang},
title = {BUB1 Promotes Gemcitabine Resistance in Pancreatic Cancer Cells by Inhibiting Ferroptosis},
journal = {Cancers},
year = {2024},
volume = {16},
number = {8},
pages = {1540},
doi = {10.3390/cancers16081540}
}
EUVIMED